| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,091,255 | 10 | 100 |
| Milligan Michael Lee | See Remarks | 0 | $0 | 1 | $5,119 | $-5,119 |
| Pinto Joshua | President | 0 | $0 | 1 | $21,093 | $-21,093 |
| BERNS PAUL L | See Remarks | 0 | $0 | 1 | $34,459 | $-34,459 |
| Aurora Daljit Singh | See Remarks | 0 | $0 | 7 | $1.03M | $-1.03M |
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with …
Over the last 12 months, insiders at Neumora Therapeutics, Inc. Common Stock have bought $0 and sold $1.09M worth of Neumora Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Neumora Therapeutics, Inc. Common Stock have bought $26.02M and sold $867,948 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,915,700 shares for transaction amount of $5M was made by Burow Kristina () on 2025‑10‑27.
| 2026-08-21 | Sale | Aurora Daljit Singh | See Remarks | 41,608 0.022% | $1.60 | $66,380 | -58.43% | |
| 2026-08-20 | Sale | Aurora Daljit Singh | See Remarks | 134,452 0.0725% | $1.51 | $203,587 | -55.42% | |
| 2026-08-19 | Sale | Aurora Daljit Singh | See Remarks | 61,918 0.0335% | $1.65 | $101,917 | -58.68% | |
| 2026-08-18 | Sale | Aurora Daljit Singh | See Remarks | 69,149 0.0361% | $1.59 | $109,622 | -58.25% | |
| 2026-08-17 | Sale | Aurora Daljit Singh | See Remarks | 146,706 0.0782% | $1.50 | $220,135 | -54.49% | |
| 2026-02-17 | Sale | BERNS PAUL L | See Remarks | 9,819 0.0058% | $3.51 | $34,459 | -53.39% | |
| 2026-02-17 | Sale | Aurora Daljit Singh | See Remarks | 6,165 0.0037% | $3.56 | $21,917 | -53.39% | |
| 2026-02-17 | Sale | Pinto Joshua | President | 5,967 0.0036% | $3.54 | $21,093 | -53.39% | |
| 2026-02-17 | Sale | Milligan Michael Lee | See Remarks | 1,436 0.0009% | $3.56 | $5,119 | -53.39% | |
| 2025-11-11 | Sale | Aurora Daljit Singh | See Remarks | 114,703 0.0741% | $2.68 | $307,026 | -34.18% | |
| 2025-10-27 | Burow Kristina | 1.92M 1.3366% | $2.61 | $5M | -31.23% | |||
| 2025-10-27 | ARCH Venture Partners XII, LLC | 10 percent owner | 1.92M 1.3366% | $2.61 | $5M | -31.23% | ||
| 2025-10-27 | ARCH Venture Partners X, LLC | 10 percent owner | 1.92M 1.3366% | $2.61 | $5M | -31.23% | ||
| 2025-02-18 | Sale | BERNS PAUL L | See Remarks | 13,871 0.0083% | $1.69 | $23,468 | -4.05% | |
| 2025-02-18 | Sale | Lenz Robert A. | Head of R&D | 5,614 0.0033% | $1.67 | $9,383 | -4.05% | |
| 2025-02-18 | Sale | Aurora Daljit Singh | Chief Strategy Officer | 8,565 0.0051% | $1.68 | $14,347 | -4.05% | |
| 2025-02-18 | Sale | Pinto Joshua | President | 8,048 0.0048% | $1.67 | $13,477 | -4.05% | |
| 2025-02-18 | Sale | Milligan Michael Lee | See Remarks | 1,978 0.0012% | $1.69 | $3,351 | -4.05% | |
| 2024-10-18 | Sale | Fust Matthew K | director | 14,049 0.0149% | $17.03 | $239,319 | -89.93% | |
| 2024-10-17 | Sale | Fust Matthew K | director | 7,739 0.0082% | $17.01 | $131,643 | -90.18% |
| Burow Kristina | 6046907 3.2182% | $3.45M | 16 | 0 | +3% | |
| ARCH Venture Partners X, LLC | 10 percent owner | 6046907 3.2182% | $3.45M | 2 | 0 | <0.0001% |
| ARCH Venture Partners XII, LLC | 10 percent owner | 6046907 3.2182% | $3.45M | 15 | 0 | +3.29% |
| Gosebruch Henry O | President & CEO | 15000 0.008% | $8,563.50 | 1 | 0 | <0.0001% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$130,095 | 43 | 45.19% | $111.24M | |
$77,146,704 | 43 | 13.28% | $93.12M | |
Neumora Therapeutics, Inc. Common Stock (NMRA) | $63,049,419 | 31 | 2.87% | $107.27M |
| Increased Positions | 60 | +61.86% | 16M | +30.87% |
| Decreased Positions | 37 | -38.14% | 4M | -7.47% |
| New Positions | 26 | New | 6M | New |
| Sold Out Positions | 14 | Sold Out | 2M | Sold Out |
| Total Postitions | 120 | +23.71% | 64M | +23.4% |
| Softbank Group Corp. | $10,858.00 | 3.92% | 6.54M | 0 | 0% | 2025-09-30 |
| Mic Capital Management Uk Llp | $7,405.00 | 2.67% | 4.46M | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $7,235.00 | 2.61% | 4.36M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $6,722.00 | 2.42% | 4.05M | -713,736 | -14.98% | 2025-09-30 |
| Fmr Llc | $5,813.00 | 2.1% | 3.5M | -934 | -0.03% | 2025-09-30 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | $5,493.00 | 1.98% | 3.31M | 0 | 0% | 2025-09-30 |
| Iconiq Capital, Llc | $4,248.00 | 1.53% | 2.56M | 0 | 0% | 2025-09-30 |
| Lunate Capital Ltd | $3,526.00 | 1.27% | 2.12M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $3,334.00 | 1.2% | 2.01M | +776,856 | +63.09% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $3,217.00 | 1.16% | 1.94M | -164,929 | -7.84% | 2025-09-30 |